Figure 5.

The epithelial Na⁺ channel inhibitor benzamil lowers blood pressure in desmopressin (dDAVP)-infused Liddle mice. Successive administration of benzamil (1.4 mg/kg body wt) for 3 days lowered systolic blood pressure (SBP; A) and mean arterial pressure (MAP; B) in dDAVP-infused (100 ng/h) Liddle mice but not in dDAVP-infused wild-type (WT) or pseudohypoaldosteronism type 1 (PHA1) mice. *P < 0.05 by a Kruskal–Wallis test before and after benzamil treatment. n = 7 WT mice, 8 Liddle mice, and 7 PHA1 mice. NS, not significant.